Infectex, a Russian biomed company, is readying for market entry its SQ109 drug candidate “unparalleled elsewhere in the world,” as the developers say.
Clinical trials for the candidate were completed earlier this year. Infectex claims this is the first new proven drug for tuberculosis in the global market in four decades.
The 2b-3 phase clinical trials were conducted in seven clinical centers in Russia and took six months. A reported 140 patients completed active therapy and showed quantifiable improvements.
Prof. Sergei Borisov of the anti-tuberculosis center at the Moscow City Department of Healthcare confirmed that the SQ109 has demonstrated safety, efficacy, and good tolerance. “Tests have proved that by the end of the sixth month the SQ109-testing patient group, combining the candidate with conventional therapy, showed an up to 80% bacterial generation reduction rate, compared to 61% in a conventional approach plus placebo,” Prof. Borisov said.
The SQ109 is a small 1,2-ethylenediamine molecule which is said to possess three unique action mechanisms that differ from those of other antibiotics used in tuberculosis therapy.